title: Incorporation of cis-9,trans-11 or trans-10,cis-12 conjugated linoleic acid into plasma and cellular lipids in healthy men.
abstract: This study investigated the incorporation of cis-9,trans-11 conjugated linoleic acid (c9,t11 CLA) and trans-10,cis-12-CLA (t10,c12 CLA) into plasma and peripheral blood mononuclear cell (PBMC) lipids when consumed as supplements highly enriched in these isomers. Healthy men (n = 49, age 31 +/- 8 years) consumed one, two, and four capsules containing approximately 600 mg of either c9,t11 CLA or t10,c12 CLA per capsule for sequential 8 week periods followed by a 6 week washout before consuming the alternative isomer. Both isomers were incorporated in a dose-dependent manner into plasma phosphatidylcholine (PC) (c9,t11 CLA r = 0.779, t10,c12 CLA r = 0.738; P < 0.0001) and cholesteryl ester (CE) (c9,t11 CLA r = 0.706, t10,c12 CLA r = 0.788; P < 0.0001). Only t10,c12 CLA was enriched in plasma nonesterified fatty acids. Both c9,t11 CLA and t10,c12 CLA were incorporated linearly into PBMC total lipids (r = 0.285 and r = 0.273, respectively; P < 0.0005). The highest concentrations of c9,t11 CLA and t10,c12 CLA in PBMC lipids were 3- to 4-fold lower than those in plasma PC and CE. These data suggest that the level of intake is a major determinant of plasma and PBMC CLA content, although PBMCs appear to incorporate both CLA isomers less readily.
authors.affiliation: Institute of Human Nutrition, University of Southampton, Southampton, SO16 7PX UK. g.c.burdge@soton.ac.uk
authors.forename: Graham C
authors.initials: GC
authors.lastname: Burdge
authors.forename: Berit
authors.initials: B
authors.lastname: Lupoli
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Russell
authors.forename: Sabine
authors.initials: S
authors.lastname: Tricon
authors.forename: Samantha
authors.initials: S
authors.lastname: Kew
authors.forename: Tapati
authors.initials: T
authors.lastname: Banerjee
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Shingfield
authors.forename: David E
authors.initials: DE
authors.lastname: Beever
authors.forename: Robert F
authors.initials: RF
authors.lastname: Grimble
authors.forename: Christine M
authors.initials: CM
authors.lastname: Williams
authors.forename: Parveen
authors.initials: P
authors.lastname: Yaqoob
authors.forename: Philip C
authors.initials: PC
authors.lastname: Calder
mesh_terms: D000328:Adult; D002788:Cholesterol Esters / Q000737:chemistry; D018592:Cross-Over Studies; D019587:Dietary Supplements; D004311:Double-Blind Method; D005227:Fatty Acids / Q000737:chemistry; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000737:chemistry; D008041:Linoleic Acids / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D008055:Lipids / Q000096:biosynthesis*; D008297:Male; D010713:Phosphatidylcholines / Q000737:chemistry
chemical_list: C094849:10,12-octadecadienoic acid; D002788:Cholesterol Esters; D005227:Fatty Acids; D008041:Linoleic Acids; D044243:Linoleic Acids, Conjugated; D008055:Lipids; D010713:Phosphatidylcholines; C046938:9,11-linoleic acid